Cimicoxib is a novel COX-2 inhibitor drug approved for use in dogs. Assessing pharmacokinetic profiles in target species is pivotal for extra label applications. The purpose of the present study was to evaluate the pharmacokinetic profiles of cimicoxib after intra-gastric administration in six healthy jennies. Plasma concentrations of cimicoxib were determined by HPLC with fluorescence detector. A pilot study was carried out with two animal groups (n = 3) in fasted or fed conditions receiving 2 mg/kg of cimicoxib. Due to the relatively low Cmax (0.03 μg/mL) from the pilot study, the dose was increased (5 mg/kg) for the subsequent full scale cross-over study. Single administration of 5 mg/kg did not show any adverse effects. However, the Cmax (0.02 μg/mL) and AUC (0.14 hour*μg/mL) values obtained after 5 mg/kg administration were not dose dependent compared to those in the 2 mg/kg pilot study. The results from this study could provide basic but essential information for the use of cimicoxib. Further pharmacodynamic studies are required to assess clinical efficacy in donkeys at these low plasma concentrations.

Pharmacokinetics of the Novel Cyclooxygenase 2 Inhibitor Cimicoxib in Donkeys

SGORBINI, MICAELA;GIORGI, MARIO
2014-01-01

Abstract

Cimicoxib is a novel COX-2 inhibitor drug approved for use in dogs. Assessing pharmacokinetic profiles in target species is pivotal for extra label applications. The purpose of the present study was to evaluate the pharmacokinetic profiles of cimicoxib after intra-gastric administration in six healthy jennies. Plasma concentrations of cimicoxib were determined by HPLC with fluorescence detector. A pilot study was carried out with two animal groups (n = 3) in fasted or fed conditions receiving 2 mg/kg of cimicoxib. Due to the relatively low Cmax (0.03 μg/mL) from the pilot study, the dose was increased (5 mg/kg) for the subsequent full scale cross-over study. Single administration of 5 mg/kg did not show any adverse effects. However, the Cmax (0.02 μg/mL) and AUC (0.14 hour*μg/mL) values obtained after 5 mg/kg administration were not dose dependent compared to those in the 2 mg/kg pilot study. The results from this study could provide basic but essential information for the use of cimicoxib. Further pharmacodynamic studies are required to assess clinical efficacy in donkeys at these low plasma concentrations.
2014
Kim, T. W.; Della Rocca, G.; Di Salvo, A.; Owen, H.; Sgorbini, Micaela; Giorgi, Mario
File in questo prodotto:
File Dimensione Formato  
Kim et al., 2014 (CX in donkeys).pdf

solo utenti autorizzati

Descrizione: Final paper
Tipologia: Versione finale editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 221.01 kB
Formato Adobe PDF
221.01 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/360267
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 10
social impact